Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 38.8% in January

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 63,600 shares, a drop of 38.8% from the December 31st total of 103,900 shares. Based on an average daily trading volume, of 2,230,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.2% of the company’s stock are short sold.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI traded down $0.26 during midday trading on Wednesday, reaching $4.26. The company’s stock had a trading volume of 9,161 shares, compared to its average volume of 86,313. The firm has a 50 day moving average price of $4.31 and a 200-day moving average price of $3.07. The stock has a market capitalization of $19.55 million, a P/E ratio of -0.27 and a beta of 2.42. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94.

Wall Street Analyst Weigh In

Separately, Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a report on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.